EMA Authorised: Nemluvio (nemolizumab) — Galderma International

View source ↗

Summary

The European Medicines Agency has authorised nemolizumab (Nemluvio) for use in atopic dermatitis and prurigo, marking a new monoclonal antibody therapy from Gal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis
• Prurigo

Drugs mentioned

• NEMLUVIO (NEMOLIZUMAB-ILTO)

Snippet

Status: Authorised. Therapeutic area: Dermatitis, Atopic;Prurigo. MAH: Galderma International. Decision date: 08/01/2026